Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (151-160 of 635) with videos related to

Pageof 64
Sort By:
Journal of the American Society of Nephrology : JASN|September 19, 2019
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS ProgramBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
European Heart Journal|May 6, 2005
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trialPierre Théroux, Paul W Armstrong, Kenneth W Mahaffey, et al.
Trials|June 21, 2013
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapyRenato D Lopes, Yuliya Lokhnygina, Victor Hasselblad, et al.
American Heart Journal|December 21, 2018
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trialClaes Held, Harvey D White, Ralph A H Stewart, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2022
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE TrialDavid M Charytan, Jie Yu, Meg J Jardine, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 12, 2025
Deep Learning Chest X-Ray Age, Epigenetic Aging Clocks and Associations with Age-Related Subclinical Disease in the Project Baseline Health StudyJay Chandra, Sarah Short, Fatima Rodriguez, et al.
American Heart Journal|July 31, 2013
Results of a reevaluation of cardiovascular outcomes in the RECORD trialKenneth W Mahaffey, Gail Hafley, Sheila Dickerson, et al.
Trials|April 11, 2020
Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated eventsAlexander C Fanaroff, Ghazala Haque, Betsy Thomas, et al.
Circulation|March 13, 2018
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS ProgramKarin Rådholm, Gemma Figtree, Vlado Perkovic, et al.
European Journal of Clinical Investigation|May 28, 2011
Determinants of plasma vitamin D levels in patients with acute coronary syndromesGabriella Rodriguez, Aijing Z Starr, Grazyna Z Czernuszewicz, et al.
Pageof 64

Showing results (151-160 of 635) with videos related to

Sort By:
Pageof 64
Journal of the American Society of Nephrology : JASN|September 19, 2019
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS ProgramBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
European Heart Journal|May 6, 2005
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trialPierre Théroux, Paul W Armstrong, Kenneth W Mahaffey, et al.
Trials|June 21, 2013
Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapyRenato D Lopes, Yuliya Lokhnygina, Victor Hasselblad, et al.
American Heart Journal|December 21, 2018
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trialClaes Held, Harvey D White, Ralph A H Stewart, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 22, 2022
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE TrialDavid M Charytan, Jie Yu, Meg J Jardine, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|August 12, 2025
Deep Learning Chest X-Ray Age, Epigenetic Aging Clocks and Associations with Age-Related Subclinical Disease in the Project Baseline Health StudyJay Chandra, Sarah Short, Fatima Rodriguez, et al.
American Heart Journal|July 31, 2013
Results of a reevaluation of cardiovascular outcomes in the RECORD trialKenneth W Mahaffey, Gail Hafley, Sheila Dickerson, et al.
Trials|April 11, 2020
Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated eventsAlexander C Fanaroff, Ghazala Haque, Betsy Thomas, et al.
Circulation|March 13, 2018
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS ProgramKarin Rådholm, Gemma Figtree, Vlado Perkovic, et al.
European Journal of Clinical Investigation|May 28, 2011
Determinants of plasma vitamin D levels in patients with acute coronary syndromesGabriella Rodriguez, Aijing Z Starr, Grazyna Z Czernuszewicz, et al.
Pageof 64